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Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), and infantile Refsum disease (IRD) are clinically
overlapping syndromes, collectively called “peroxisome biogenesis disorders” (PBDs), with clinical features being
most severe in ZS and least pronounced in IRD. Inheritance of these disorders is autosomal recessive. The peroxisome
biogenesis disorders are genetically heterogeneous, having at least 12 different complementation groups (CGs). The
gene affected in CG1 is PEX1. Approximately 65% of the patients with PBD harbor mutations in PEX1. In the
present study, we used SSCP analysis to evaluate a series of patients belonging to CG1 for mutations in PEX1 and
studied phenotype-genotype correlations. A complete lack of PEX1 protein was found to be associated with severe
ZS; however, residual amounts of PEX1 protein were found in patients with the milder phenotypes, NALD and
IRD. The majority of these latter patients carried at least one copy of the common G843D allele. When patient
fibroblasts harboring this allele were grown at 30C, a two- to threefold increase in PEX1 protein levels was
observed, associated with a recovery of peroxisomal function. This suggests that the G843D missense mutation
results in a misfolded protein, which is more stable at lower temperatures. We conclude that the search for the
factors and/or mechanisms that determine the stability of mutant PEX1 protein by high-throughput procedures
will be a first step in the development of therapeutic strategies for patients with mild PBDs.
Introduction
Peroxisomes are subcellular organelles, present in virtu-
ally every eukaryotic cell, that catalyze a variety of es-
sential functions. In humans, these functions include fat-
ty-acid b-oxidation, etherphospholipid biosynthesis,
fatty-acid a-oxidation, isoprenoid biosynthesis, and other
functions (van den Bosch et al. 1992; Wanders and Tager
1998). Disorders resulting from defects in peroxisom-
al biogenesis include Zellweger syndrome (ZS [MIM
214100]), neonatal adrenoleukodystrophy (NALD
[MIM 202370]), infantile Refsum disease (IRD [MIM
266510]), and rhizomelic chondrodysplasia punctata
type 1 (RCDP1 [MIM 215100]) (Lazarow and Moser
1995; Wanders 1999). The first three diseases, listed in
order of decreasing severity, represent a continuum of
clinical features, whereas RCDP displays a distinct phe-
notype (Moser et al. 1995). Patients with ZS show neu-
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rological and hepatic abnormalities, renal cysts, and
characteristic facial dysmorphic stigmata; these patients
die at ages !1 year. Patients with IRD display the mildest
phenotype, with no significant cerebral abnormalities,
and survive until or even beyond adolescence (Lazarow
and Moser 1995). NALD is intermediate between ZS
and IRD in severity, and patients usually die in early
childhood. In recent years, an increasing number of pro-
teins, named “peroxins,” that are involved in the bio-
genesis of peroxisomes have been identified (Sacksteder
and Gould 2000). Complementation studies with mam-
malian fibroblasts have so far shown the existence of 12
different groups; in 11 of these, the defective PEX gene
is known (Moser 1999). Complementation group 1
(CG1) is the largest, characterized by mutations in
HsPEX1 (PEX1 [MIM 602136]), a gene coding for a
143-kD AAA (ATPases associated with diverse cellular
activities) protein (Portsteffen et al. 1997; Reuber et al.
1997; Tamura et al. 1998a). Approximately 65% of pa-
tients affected with peroxisome biogenesis disorders
(PBDs [MIM 601539]) belong to this group (Moser et
al. 1995; Maxwell et al. 1999; Wanders et al. 1999).
The clinical phenotypes of patients belonging to this
group cover a spectrum of severity, ranging from ZS to
NALD and IRD.
With respect to the molecular basis of these pheno-
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Table 1
Intronic Primer Pairs Used to Amplify the HsPEX1 Exons for SSCP Analysis
Sequence Designation
Sense (s) or
Antisense (as)
5′-CTTTGCGGCGCTAGGGT-3′ 5inex1 s
5′-GGCTGAAGATCAGGTGGCTC-3′ 3inex1 as
5′-AAAATGTATACGAAAACCTTTTTTCC-3′ 5inex2 s
5′-ATGTGATATTAGAAGAAAGTTATTGC-3′ 3inex2 as
5′-GATTACATAGACTACATATACACCC-3′ 5inex3 s
5′-CATTGATATTGTGAAGTAATTTAACC-3′ 3inex3 as
5′-ATTTTTTTTAACTAGATATGGAGTGG-3′ 5inex4 s
5′-GCACATTCATTTCTACTTTGGACTC-3′ 3inex4 as
5′-AGAAATGAATGTGCACTAATGAGC-3′ 5inex5 s
5′-TAAGAATTCGGAAATACATGAATGGCACAG-3′ 3exex5 as
5′-CGCGTCAGCAACCTCTG-3′ 5exex5 s
5′-TGTTTAAGCCACATAAAATTTCTCC-3′ 3inex5 as
5′-TAGAAGCTAATATATCAATATTTATGC-3′ 5inex6 s
5′-CAACTAGAAATCTTACAAAACGTG-3′ 3inex6 as
5′-GTTAAAGTTAAGTTCAGATATGAGG-3′ 5inex7 s
5′-TACAACTATTTAAATAGAAAAAAAAGTC-3′ 3inex7 as
5′-CTCTGTTTCAGTACTAACTCTGC-3′ 5inex8 s
5′-CAAGGTGTTACAAGGAACTTCATA-3′ 3inex8 as
5′-AAGACATACTTTGAAATGTAAAACTG-3′ 5inex9 s
5′-TTGACATTAACATCTACTTTAATATTTAC-3′ 3inex9 as
5′-TCAGTCTTTTATCATGTAACTATGTAT-3′ 5inex10 s
5′-TATTAAATGTTACAGAAAAATGAACAC-3′ 3inex10 as
5′-CTGAATCTTGGTGGTTGCC-3′ 5inex11 s
5′-GATATGTGTATTTATTAGATTGACAG-3′ 3inex11 as
5′-GCACTGAAATGATACTGAAACCAT-3′ 5inex12 s
5′-GACTGACAAAAGAACAAGACCTTA-3′ 3inex12 as
5′-TACTTTTCCTAAGCTTTTGCACTA-3′ 5inex13 s
5′-TATAAAAGGGACATAATTCAATAATC-3′ 3inex13 as
5′-CTGATTTTCTCCAAATATACATTCAA-3′ 5ines14 s
5′-TAGAAAGAAGATTCCAAGTTCAGG-3′ 3inex14 as
5′-TATAGTGAATAATAACTAGTAAAAGAAG-3′ 5inex15 s
5′-CATAAAGCCAAAGCCAATAATACAG-3′ 3inex15 as
5′-TTAGTCATTTCTGTTTAGACTTGAG-3′ 5inex16 s
5′-TTTACACTTTGAAATGGCTAACTG-3′ 3inex16 as
5′-ATTTCCATGATTCATTTACACTTAG-3′ 5inex17 s
5′-TGATTGATAAATAATAACAGAGTCAG-3′ 3inex17 as
5′-ACTTTGCCAACTATGAAGCCTG-3′ 5inex18 s
5′-ACCAAAATCTGATGACATGATGAC-3′ 3inex18 as
5′-GTCATCATGTCATCAGATTTTGGT-3′ 5inex19 s
5′-TAGCATTTGTTGGGTTTTGGAC-3′ 3inex19 as
5′-ATTTATGAAGAAAATCATAAGATACAC-3′ 5inex20 s
5′-TGACATTGTACTTCTTTTATCACTC-3′ 3inex20 as
5′-TAAAATTGTTTACATCTTTAAACTGG-3′ 5inex21 s
5′-AGAAATCACTGCAACTTTACACC-3′ 3inex21 as
5′-GTTTTTTCTCTCCCCCTCTTCC-3′ 5inex22 s
5′-TAAGAAGTTTTAACAATTATAATGAGG-3′ 3inex22 as
5′-TTTTACATCCTTAATTTAACTCTTCG-3′ 5inex23 s
5′-ACTTGTAATAGTAGCTGTACTTCC-3′ 3inex23 as
5′-ATCCATTATCTTTTGTTTTGTAATGG-3′ 5inex24 s
5′-CTGTTACAACATATGGAAAAGCC-3′ 3inex24 as
NOTE.—Examples for designations: 5inexE is the sense primer attaching to the 5′ end of
exon E, and 3inexE is the antisense primer attaching to the 3′ end of exon E.
types, two relatively common alleles in theHsPEX1 gene
have been identified: one allele with a missense mutation
(G843D) associated with milder PBDs (Portsteffen et al.
1997; Reuber et al. 1997; Imamura et al. 1998a; Collins
and Gould 1999; Ga¨rtner et al. 1999; Maxwell et al.
1999), and a second allele with a 1-bp insertion (c.2097-
2098insT) resulting in a premature stop at amino acid
740, a mutation that is often present in patients with
classical ZS (Collins and Gould 1999; Maxwell et al.
1999). Fibroblasts harboring the G843D allele are char-
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Figure 1 Common mutations of CG1, and resulting PEX1 protein levels. A, The G843D allele (I), identified in patients 1, 2, 4, 7, and
10 by SSCP analysis and sequencing of exon 15. The genotypes of patients indicated by an asterisk (*) were identified by sequence analysis.
ndp not denatured control. Numbers 1–12 indicate CG1 patients 1–12. B, The c.2097-2098insT allele (indicated by “II”), detected in patients
6 and 10 by SSCP analysis and sequencing of exon 13. The frameshift in one allele leads to a premature stop at codon 740 (P740X). “III”
indicates a newly identified HsPEX1 allele in patient 8, which results in I696M. C, Results of immunoblot analysis using polyclonal antibodies
against PEX1 protein. Patients 7 and 10, carrying the G843D allele, had residual PEX1 protein (∼5% of the normal level) and were affected
with the milder phenotypes NALD or IRD (i.e., nonclassical ZS). No PEX1 was detected in cell lysates from patient 6, who was carrying the
c.2097-2098insT allele; this patient had severe classical ZS. The PEX1 protein level in fibroblasts from patient 8 is shown for comparison. WT
p wild type; Co p control fibroblasts from patient PBD009, who has no detectable PEX1 mRNA and who exhibits ZS (Collins and Gould
1999); smaller arrow indicates unspecific protein recognized by the anti-PEX1 antibodies.
acterized by a temperature-dependent phenotype, with
restoration of catalase import and peroxisomal functions
at 30C (Imamura et al. 1998a).
In the present study, we aimed to define the relation-
ship between the genetic defects and the phenotypes of
CG1 patients. For this purpose, genomic DNA from 22
Dutch patients belonging to CG1 was investigated by
SSCP analysis and DNA sequencing. Subsequently, the
amount of PEX1 protein in fibroblasts from these pa-
tients was determined. In addition, biochemical and cell-
biological studies were performed to analyze the func-
tion of the PEX1 protein. Finally, we examined the way
in which the G843D allele led to the observed temper-
ature-dependent phenotype.
Patients, Material, and Methods
Patients
Clinical information about some of the patients in-
cluded in the present study has already been reported in
the literature. Patient 2 of our study is referred to as
“patient 9” in the report by Heymans et al. (1984),
patient 22 of our study is described in an article by
Smeitink et al. (1992), and patients 27 and 30 of our
study are referred to as “case 4” and “case 1,” respec-
tively, in the report by Budden et al. (1986).
Cell Lines and Culturing Conditions
Primary fibroblast cell lines, from 22 Dutch patients
who were assigned to CG1 by complementation analysis
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Figure 2 Genotypes and PEX1 protein levels in patients with IRD and ZS. Abbreviations are as in figure 1. A, Patient 9, affected with
IRD: (a) SSCP analysis of exon 12 showed a mobility shift (indicated by “I”); ndp not denatured control, numbers 1–12 indicate CG1 patients
1–12; (b) sequencing of exon 12 led to identification of a GrT transversion at the donor splice site (c.20711GrT) in one allele; (c) sequencing
of exon 10 revealed one c.1777GrA allele, resulting in G593R. B, Patients 11 and 12, affected with classical ZS: (a) SSCP analysis of exon
17 showed a mobility shift; (b) sequencing revealed a 1-bp deletion of nucleotide 2730 (c.2730delA), resulting in a stop codon at amino acid
960 (V960X). C, The PEX1 protein levels, investigated in cell lysates of patient fibroblasts, given as percentages of the wild-type level. No
PEX1 was found in cells of the patients with classical ZS (patients 11 and 12). Approximately 10% of the normal level of PEX1 protein was
detected in cells from patient 9, who was affected with the mild clinical phenotype IRD (nonclassical ZS).
(Wanders et al. 1999) performed at the AmsterdamMed-
ical Center, were cultured, at 8.5% CO2, in Dulbecco’s
modified Eagle medium (DMEM) supplemented with
10% (v/v) fetal calf serum, 2 mM L-glutamine, 100,000
U penicillin/liter, and 100 mg streptomycin/liter. Some
of these cell lines were transformed with the large T
antigen of SV40 virus, as described by Dodt et al. (1995).
To investigate the PEX1 protein level and the per-
oxisomal function under serum starvation, fibroblasts
were seeded, in 75-cm2 flasks and on cover slips, to 50%
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Figure 3 Increase in the PEX1 protein level of patient fibroblasts
harboring the G843D allele, at 30C. Cells were cultured for 3 d at 37C
or 30C. Cell lysates were subjected to SDS-PAGE and transferred onto
nitrocellulose. Immunoblot analysis was performed, using polyclonal
antibodies against PEX1 protein. WT p wild type (GM5659); “31”
and “27” refer to patients 31 and 27, respectively. An arrow (R) marks
the position of the PEX1 protein; the asterisk (*) denotes an unspecific
protein recognized by anti-PEX1 antibodies, which was used to correct
for an eventually unequal loading of the sample. The protein levels are
shown in table 4. A, Comparison of wild-type (GM5659) cells versus
cells from patients 31 and 27, at 30C and 37C. In comparison with
wild-type cells, we detected ∼5%–17% of the normal level of PEX1
protein in lysates of cells incubated at 37C, and ∼17%–28% of the
normal level of PEX1 protein in those incubated at 30C (see table 4
for protein levels). This increase in protein levels may be explained by
an improved stability of PEX1 at the lower temperature.B, Lower PEX1
protein level in control wild-type fibroblasts at 30C compared with that
at 37C, under the same conditions as above.
cell confluency and were cultured in serum-free Opti-
MEM (Life Technologies) for 3 d, before further anal-
ysis. In a separate experiment, subconfluent cultures, in
flasks and on cover slips, were incubated with the pro-
teasome inhibitor MG-132 (Calbiochem; final concen-
tration 7.5 mM MG-132 and 0.03% [v/v] DMSO)—or
with DMSO alone in DMEM plus supplements—for 6
h and then were processed. To evaluate the cells under
highly confluent conditions, the cultures in flasks and
on cover slips were kept for 7 d after they reached con-
fluency and then were used for analysis.
Immunofluorescence Microscopy
Fibroblasts were seeded on cover slips 1 d before the
actual experiment. The cells were processed for indirect
immunofluorescence, as described by Slawecki et al.
(1995). Polyclonal sheep anti–human catalase antibodies
were obtained from The Binding Site; labeled secondary
antibodies were acquired from standard commercial
sources. Immunofluorescence was observed with a Zeiss
Axiophot microscope.
Preparation of Cell Pellets, Western Blotting,
Generation of Antibodies, and Biochemical Assays
Cells from a 75-cm2 flask, grown to near confluency,
were harvested with trypsin, washed twice with Hanks
buffer, and resuspended in 150 ml H2O. An aliquot was
taken for protein estimation (Coomassie Protein Assay
Reagent, Pierce). The cell suspension was immediately
mixed with 5# concentrated SDS sample buffer (final
concentration 2% (w/v) SDS, 10% (v/v) glycerol, 5%
(v/v) b-mercaptoethanol, 0.002% (w/v) bromophenol
blue, and 62.5 mM Tris/HCl, pH 6.8), boiled for 5 min,
and frozen at 80C.
The cell lysates were separated by SDS-PAGE on 8%
gels (25 mg total protein/slot). The separated proteinswere
transferred onto nitrocellulose membrane for 5 h at 30
V, using a BioRad mini blot apparatus (BioRad). Western
blot analysis was performed with anti-PEX1 polyclonal
rabbit antibodies (1:15,000 dilution) andwith anti–rabbit
IgG antibodies conjugated to horseradish peroxidase as
secondary antibodies (Amersham), using the ECLwestern
blotting detection reagent (Amersham). The exposed film
(Hyperfilm ECL, Amersham) was digitized with a flatbed
scanner (Arcus II, Agfa), and PEX1 proteinwas quantified
by MacBas software (Fuji).
Anti-PEX1 antibodies were generated against the N-
terminal part of PEX1, corresponding to amino acids
2–315. For this procedure, a 945-bp fragment was am-
plified by PCR, using the primer pairs KU 397 (5′-TCGG-
GCCCATGGGATGGGGCAGCGATCGCCTG-3′) and
KU 398 (5′- CTGAGCTCGGATCCAAATACATGAAT-
GGCACAG-3′), digested with NcoI and BamHI, and
cloned downstream of the hexahistidinyl (His6) tag
into the corresponding sites of expression plasmid
pET9dNHis6. The latter plasmid was kindly provided
by G. Stier (EMBL, Heidelberg). It was derived from
pET9d (Novagen) by replacing the unique NcoI site
with a DNA fragment that encoded the His6 tag and
contained several unique endonuclease recognition
sites, includingNcoI. Tagged PEX1 proteins expressed
in Escherichia coli BL21 (DE3) were purified by Ni-
NTA chromatography under denaturing conditions (8
M urea), according to the pET system manual.
The quantification of very-long-chain fatty acids
(VLCFA) and the determination of dihydroxyacetone-
phosphate acyltransferase (DHAPAT), catalyzing the
first step in etherphospholipid biosynthesis, were per-
formed as described byWanders et al. (1995) andVreken
et al. (1998).
Mutation Analysis
Genomic DNA was prepared as described by Miller
et al. (1988), using 1 ml of lysis buffer (10 mM Tris/
HCl, pH 8.2; 400 mM NaCl; and 2 mM EDTA) for a
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Table 3
Biochemical Parameters Correlated with the PEX1 Protein Level
Biochemical Parameter Patient 9 Patient 11/Patient 12
VLCFA C26:C22 ratioa .12 .31/.48
DHAPAT activityb (nmol/2h # mg protein) 4.3 .1/.1
Catalase import Partial import into peroxisomes No import into peroxisomes
Age/condition 6 years, alive, relatively good condition Died before age 3 mo
PEX1 protein level (% of control) ∼7 0/0
Diagnosis Nonclassical ZS (IRD) Classical ZS
a Control values: mean p .04; range p .03–.07.
b Control values: 8.5  2.0 nmol/2h # mg protein.
confluent 75-cm2 flask of fibroblasts. PCR was per-
formed with intronic primer pairs encompassing exons
1–24 (see table 1). SSCP analysis was performed as de-
scribed by Portsteffen et al. (1997). Alternatively, the
SSCP reactions were performed without radioactive la-
beling, and the samples were separated on a 0.5#MDE
gel (FMC), containing 2% glycerol, 1 M urea, and 0.6
# TBE on GelBond PAG film (FMC). The DNA was
visualized by silver staining. PCR fragments showing a
mobility shift were directly sequenced. To this end, the
PCR fragments were separated on agarose and isolated.
Direct sequencing was performed by Qiagen.
Results
PEX1 Mutations in Patients from CG1 with Different
Clinical Phenotypes
One goal of this study was to investigate the genetic
differentiation of severely and mildly affected patients.
Although the biochemical diagnosis of the PBDs is well
established, the correlation between the biochemical
data and the clinical presentation is still unclear. We
analyzed 22 patients, belonging to CG1, who had dif-
ferent clinical phenotypes for mutations in PEX1. Each
of the 24 PEX1 exons were amplified from fibroblast
DNA through use of intronic primer pairs and analyzed
by SSCP (Portsteffen et al. 1997). Fragments showing
unusual patterns after electrophoretic separation were
sequenced directly, in both directions. All mutations are
depicted in table 2.
Approximately half of the alleles (21 of 44) carry a
missense mutation, with a clear prevalence of theG843D
allele (17 of 44 alleles; table 2). Apart from this allele,
we identified one other frequent allele, the c.2097-
2098insT allele, which harbors an insertion of a nucle-
otide in exon 13 leading to a premature stop at codon
740 (P740X). We found the c.2097-2098insT mutation
in 13 of 44 alleles; this means that the c.2097-2098insT
allele has a frequency of 30% among the Dutch patients
with PBD who belong to CG1. Since we observed that
this allele was not always detected by SSCP analysis, we
reinvestigated the six patients included in our previous
study (Portsteffen et al. 1997) by means of direct se-
quencing and found five of the patients to be hetero-
zygous for this c.2097-2098insT allele (Reuber et al.
1997; Collins and Gould 1999). The c.2730delA allele,
which results in a premature stop at codon 960 (V960X),
was identified in two related patients who were both
homozygous for the 1-bp deletion. The SSCP analysis
and an example of the sequencing results are given in
figure 1A, for exon 15, and in figure 1B, for exon 13.
The c.2730delA allele is described in figure 2B and in
table 2.
Correlation between Different Mutant Alleles and the
Resulting PEX1 Protein Levels
On the basis of our assumption that the phenotypes
of the patients correlate with the degree of peroxisomal
function and thus depend on functional PEX1 protein,
we investigated the steady-state levels of PEX1 protein
in fibroblasts. For this purpose, we successfully gener-
ated antibodies against PEX1. These antibodies were
directed against amino acids 2–317 of HsPEX1 and
therefore also recognize truncated proteins.
Fibroblasts from all patients were harvested and lysed
in sample buffer. Proteins were separated by SDS-PAGE,
blotted onto nitrocellulose, and probed with polyclonal
anti-PEX1 antibodies. The consequences of the twomost
common alleles for the PEX1 protein level are shown in
figure 1C and table 2.
Instead of the typical categories of ZS, NALD, and
IRD, we decided to use only two disease categories, com-
prising (1) classical ZS (craniofacial dysmorphia; severe
neurological abnormalities, including hypotonia; eye ab-
normalities; and early death) and (2) nonclassical ZS,
which includes all variants that are not classical ZS. This
second group mainly represents patients with a diagnosis
of NALD and IRD, who show less-pronounced abnor-
malities and have longer survival. The designation
“NALD” and “IRD” was also given, for those patients
in whom the diagnosis was well defined.
All fibroblasts from patients harboring the G843D
allele had amounts of residual PEX1 protein that were
3%–15% of that found in normal fibroblasts (table 2A).
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Table 4
Higher PEX1 Protein Levels, in Cells Harboring the G843D Allele, at 30C Compared with 37C
PATIENT
MUTATION (CDNA LEVEL, PROTEIN LEVEL)
PEX PROTEIN LEVEL
(% of control)
DIAGNOSIS AND
CONDITION
CATALASE IMPORTa
I II At 37C At 30C At 37C At 30C
10 c.2528GrA, G843D c.2097-2098insT, P740X ∼5 ∼17 Nonclassical ZS (IRD),
aged 41years, alive
() 
26 c.2528GrA, G843D c.2528GrA, G843D ∼15 ∼28 Nonclassical ZS (IRD),
aged 8 years, alive
 
27 c.2528GrA, G843D c.2528GrA, G843D ∼10 ∼18 Nonclassical ZS (IRD),
aged 27 years, alive
 
31 c.2528GrA, G843D c.2528GrA, G843D ∼7 ∼24 Nonclassical ZS (IRD),
aged 45 years, alive
 
1 c.2528GrA, G843D c.2846GrA, R949Q ∼50 ∼60 Classical ZS; died at
age 3 mo
… ()
Control … … 100 80–90 …  
a … p no catalase import, () p 10% catalase import,  p 25% catalase import,  p 75% catalase import, and  p
100% catalase import.
The clinical presentations of these patients indicated
milder phenotypes (i.e., nonclassical ZS) like NALD or
IRD, and survival times were 12 years. An exception
was patient 1, who exhibited ∼50% PEX1 immuno-
reactive protein but nevertheless showed all the signs
and symptoms of classical ZS. It is possible that the
second allele, R949Q, is expressed in this patient but is
nonfunctional, and that it interferes with the residual
protein expressed from the G843D allele.
No protein was expressed from the c.2097-2098insT
(P740X) allele, as demonstrated by analysis of patients
17, 19, 23, 6, and 16 (table 2B). These findings are in
line with the results of Maxwell et al. (1999), who de-
tected almost no PEX1 mRNA. All patients who were
either homozygous for this allele—or heterozygous for
this allele, with the other allele being a different “null
allele”—had no detectable PEX1 protein and were all
diagnosed with classical ZS. For two patients, the age
at death is unknown because there was no further follow
up, owing to different reasons. All other patients died
within the first 2 years of life.
Two additional examples of patients with a combina-
tion of different mutant alleles also demonstrate the effect
of the mutations on the PEX1 protein level (fig. 2). Patient
9 was heterozygous for an allele with a splice-donor–site
mutation in exon 12 (c.20711GrT) and for an allele
with a missense mutation, resulting in G593R (fig. 2A).
As seen in figure 2C, the protein level was !10% of that
in wild-type fibroblasts. The allele carrying the splice-site
mutation is likely to produce unstable RNA and, prob-
ably, no protein (Maquat 1995). No abnormally sized
protein bandwas visible with anti-PEX1 antibodies.Most
likely, the G593R allele accounts for the residual PEX1
protein detected (∼7% of normal) in this patient with
nonclassical ZS (IRD). Two identical twins (patients 11
and 12) were homozygous for the deletion of nucleotide
2730 (c.2730delA; fig. 2B). No PEX1 protein was de-
tectable in fibroblasts from these patients. As mentioned
above, this deletion would lead to a premature stop at
amino acid 960. No abnormally sized protein bands re-
acting with the PEX1 antibodies were observed.
Since the presence of detectable PEX1 protein does
not guarantee its functionality, as shown above for pa-
tient 1, we included biochemical parameters. Although
the function of PEX1 is not defined yet, it is likely that
PEX1 plays a significant role in the import of peroxi-
somal matrix proteins into the peroxisomes (Portsteffen
et al. 1997; Reuber et al. 1997; Collins et al. 2000;
Sacksteder and Gould 2000). As a direct measure of
PEX1 activity in cells, we determined (1) the activity of
the peroxisomal enzyme DHAPAT, and (2) the VLCFA
levels (ratio of C26:C22) in fibroblasts. These are in-
dicators of two distinct biochemical pathways: plas-
malogen biosynthesis and peroxisomal b-oxidation. The
results of biochemical analyses for all patients are sum-
marized in table 2.
As can be judged from the mean values given in table
2, there is a clear tendency for a more severe biochemical
phenotype for the patients with classical ZS. However,
it is not reliable to assign a patient to one of the groups
(nonclassical ZS or classical ZS) solely on the basis of
these two biochemical parameters. In this regard, the
additional determination of the protein level in combi-
nation with the mutation analysis will be more valuable.
An example of the combination of these data is given
in table 3, for patient 9 versus patients 11 and 12. Judg-
ing from VLCFA levels, DHAPAT activity, and partial
localization of catalase in peroxisomes, it can be con-
cluded that patient 9 seems to be mildly affected. These
observations are in line with the diagnosis of nonclassical
ZS (IRD). Patients 11 and 12, who lacked PEX1 com-
pletely, exhibited fully developed classical ZS with no
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Figure 4 Catalase import in peroxisomes of patient fibroblasts harboring the G843D allele and different second mutated PEX1 alleles.
Fibroblasts were cultured for 3 d at either 30C or 37C and then treated for indirect immunofluorescence. Catalase staining was diffuse,
indicating a cytoplasmic localization at 37C. At 30C, catalase was imported into peroxisomes in most of the cells from patient 10 (as indicated
by the punctuate staining pattern) but in only ∼10% of the cells of patient 1. The punctuate structures colocalized with the staining for the
peroxisomal membrane protein PMP70 (data not shown).
import of peroxisomal matrix proteins, strongly elevated
levels of VLCFA, almost no DHAPAT activity, and death
before age 3 mo. The effect of a total deficiency of PEX1
protein was similar in all patients (see table 2) and al-
ways resulted in classical ZS.
Elevation of the PEX1 Protein Level in Fibroblasts
Harboring the G843D Allele, at 30C
When we examine the PEX1 protein levels in all pa-
tient fibroblasts with the G843D allele, the steady-state
level is reduced to 5%–10% of that in control fibro-
blasts. Since the mRNA level in these patients seemed
to be normal (Maxwell et al. 1999), a likely possibility
is that the mutant PEX1 protein is degraded immedi-
ately. It has been reported that missense mutations often
result in partially misfolded proteins that undergo rapid
degradation (Waters et al. 1998a, 2000; Bross et al.
1999). The possibility that the PEX1 G843D protein is
less stable is supported by the temperature-sensitive phe-
notype that has been described for fibroblasts harboring
this allele (Imamura et al. 1998a). Such a temperature
effect is a rather common feature of proteins that arise
from alleles with missense mutations, since misfolding
is reduced at the lower temperature (Bross et al. 1999).
This results in higher protein levels, leading to an almost
normal phenotype. To test this prediction, we investi-
gated the PEX1 function by monitoring the import of
catalase and by analyzing the PEX1 protein level under
various conditions. The following conditions were cho-
sen to test the stability: (1) cells were cultured at a tem-
perature of 30C and were compared to cells cultured
at 37C; (2) the growth rate of the culture was modified
by serum starvation; (3) the confluency of the fibroblasts
was varied; and (4) cells were grown in the presence of
proteasome inhibitors. Conditions 2 and 3 were selected
because it has been reported that differences in perox-
isomal import of mutant cell lines depend on the growth
rate (serum starvation) or the confluency of the culture
(Wiemer et al. 1991).
We selected cells from patients 10, 26, 27, and 31,
who were all homozygous or heterozygous for the
G843D allele, together with control cells (table 4). We
first investigated the temperature effect on the import of
catalase. Catalase is a sensitive indicator of peroxisomal-
import defects because of its very inefficient import even
under normal conditions (Lazarow et al. 1982; Warren
et al. 1998). Specifically, we cultured fibroblasts from
patients and a control for 3 d at 37C and at 30C. The
overall results are listed in table 4. Examples of the im-
munoblots with PEX1 proteins are given in figure 3, and
the immunofluorescence results are shown in figure 4.
In fibroblasts from patients 10, 26, 27, and 31, the
PEX1 protein level was two- to threefold higher at the
lower temperature than at the higher temperature, in
contrast to control cells, which even showed slightly re-
duced PEX1 protein levels at the lower temperature (ta-
ble 4). Each cell line was investigated at least twice, with
similar results. At this temperature, the import capabil-
ities for catalase were completely restored. All these pa-
tients share a milder clinical phenotype and relatively
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Figure 5 Mutations in PEX1. A, Exons coding for the first AAA cassette of PEX1, depicted in light gray, and exons coding for the second
AAA cassette, in dark gray. Mutations identified by our group (28 CG1 patients; Portsteffen et al. 1997; and the present study) are marked
above the row of exons, and mutations identified by other groups (Reuber et al. 1997; Imamura et al. 1998a; Tamura et al. 1998a; Collins
and Gould 1999; Ga¨rtner et al. 1999; Maxwell et al. 1999) are marked below the row of exons. Gray symbols p cell lines from identical
patients were analyzed by different groups. Each symbol represents a single PEX1 allele. The numbers refer to the references given below. B,
Descriptions of the mutations, sorted by exon, with designations given at the cDNA and the protein level whenever possible. A silent mutation
at codon 777 (G777) that seems to be a polymorphism, as well as an intronic deletion in intron 11, both of which are described by Collins
and Gould (1999), are not included. s.d.p splice donor site. References—1p Reuber et al. (1997); 2p Portsteffen et al. (1997); 3p Ga¨rtner
et al. (1999); 4 p Tamura et al. (1998a); 5 p Maxwell et al. (1999); 6 p Collins and Gould (1999); 7 p Imamura et al. (1998a).
extended survival times; patient 1, however, displayed a
different picture. Although the PEX1 level in the cells
from this patient, at the lower temperature, rose from
50% (at 37C) to 60% of the normal level, the effect
on the restoration of catalase import was only minimal.
The clinical phenotype of this patient is described as
classical ZS, with death at age 3 mo. As mentioned
above, the second allele (R949Q) seems to be expressed
but the protein may be nonfunctional and may interfere
with the mutant protein from the G843D allele, thus
preventing the alleviating effect of this allele.
In the second experiment, we investigated whether the
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observed effect of temperature (the higher import rate
of catalase) may be related to the lower growth rate at
30C, as has been reported for certain cell lines (Wiemer
et al. 1991). We repeated the experiment described
above, for patient 31 and for normal fibroblasts, with
serum-free medium. This led to a substantial reduction
in the growth of the investigated cells. Whereas the im-
port in cells that were grown at 30C in serum-free me-
dium was restored, no restoration was observed in cells
that were grown at 37C in serum-free medium. Normal
fibroblasts showed no import abnormalities under these
conditions.
In the third experiment we compared cells—from pa-
tients 27 and 31 and from controls—that were at initial
confluency versus cells that had been left completely con-
fluent for 1 wk, and we then investigated catalase import
and the PEX1 protein level.We observed a slight increase
in catalase import and a minimal increase in the PEX1
level in all patient cells; however, the effect was far less
pronounced than that observed in the first experiment
characterized by the temperature change (data not
shown).
Slower degradation of protein would result from a
lower activity of proteases or of the protein-degrading
machinery. To test this possibility, we incubated normal
fibroblasts and fibroblasts from patient 26 for 6 h in 7.5
mM MG-132, a proteasome inhibitor, and investigated
catalase import by immunofluorescence and the PEX1
protein level by immunoblotting. For control purposes,
we analyzed the PEX5 (MIM 600414) protein level,
which is severely reduced in PEX1-deficient cells, owing
to higher degradation, as demonstrated by pulse-chase
experiments (Dodt and Gould 1996). We noticed an in-
crease in PEX5 protein level in the presence of the pro-
teasome inhibitor, indicating that the concentration of
MG-132 was, in principle, sufficient to block the deg-
radation of PEX5. However, we could not detect any
significant increase in PEX1 protein level. In addition,
there was no apparent improvement in catalase import.
This experiment was repeated with different PEX1 de-
ficient cell lines, with similar results (data not shown).
Discussion
In principle, we can identify two groups of patients
within CG1, as studied in this article. In the first group,
there is a clear relationship between genotypes that are,
presumably, “null alleles,” and the classical ZS pheno-
type, with death of the patients at ages !1–2 years. In
these cases, we could not identify any PEX1 protein in
fibroblasts, the import for peroxisomal proteins was al-
most completely absent, and the peroxisomal functions
were severely reduced.
The second group includes all patients with genotypes
that allow residual function of the PEX1 protein andwho
display severe yet milder phenotypes of nonclassical ZS,
such as NALD and IRD. On the basis of our observations
to date, the function of the peroxisome in single cells—for
example, the import of catalase—depends on the amount
of mutated PEX1 protein and on gene dosage. We ob-
served the tendency that all fibroblasts of patients with
at least one G843D allele have PEX1 protein levels that
are ∼5% of that found in wild-type fibroblasts. Some of
the patients with two G843D alleles have a higher
amount of protein and are less severely affected. In spite
of this correlation, it is not possible to make reliable
predictions, regarding the prognosis of the milder af-
fected patients, on the basis of the protein levels them-
selves or from other routinely determined biochemical
data.
All mutant PEX1 alleles currently known, from the
present study and from other published studies, are
summarized in figure 5. The two common alleles
G843D and c.2097-2098insT account for 39% and
30%, respectively, of the CG1 alleles in our patients.
This roughly corresponds to the published results for
patients at the Kennedy Krieger Institute in Baltimore
(Collins and Gould 1999). These authors described
an allele frequency of 30% each, for both mutations.
In addition, frequencies of 25% for the G843D and
32% for the c.2097-2098insT have been reported for
Australasian probands (Maxwell et al. 1999). Other
published frequencies include 33% for the G843D
allele in a German cohort (Ga¨rtner et al. 1999) and
21% for this same allele in probands that were ex-
amined by a Japanese group (Imamura et al. 1998a).
Misfolding as a Reason for Reduced PEX1 Protein
Levels?
Recent data on genotype-phenotype relationships in
phenylketonuria may be helpful in the interpretation of
our results (Waters et al. 1998b, 2000). Waters and co-
workers investigated several missense alleles by observ-
ing their expression in different in vitro systems and by
3D-structural localization. They found that some of the
missense mutations that are changing amino acids far
from the catalytic site of phenylalanine hydroxylase lead
to misfolding of the protein monomers, to altered oligo-
merization into the tetramer, and to an accelerated pro-
teolytic degradation, finally resulting in a reduced cel-
lular protein level of the enzyme (Waters et al. 1998b,
2000). These mutant phenylalanine hydroxylases were
associated with a variability of phenotypic severity that
the authors explained by interindividual differences in
the handling of the mutant proteins (Waters et al. 2000).
Our results for the G843D allele suggest that the
amount of PEX1 protein and the peroxisomal functions
in patient fibroblasts can be influenced by environmental
conditions, such as incubation temperature or con-
fluency of the culture. Furthermore, it is likely that, on
a cellular level, ∼20% of the normal protein level is
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sufficient to allow normal catalase import. From this we
cannot directly define the amount of PEX1 protein that
would be necessary to prevent a clinical phenotype, but
we do know that 5%–15% of normal levels of func-
tional PEX1 protein is related to the milder clinical phe-
notypes. This indicates that very small changes in the
protein level may be beneficial for patients.
In this respect, it is interesting to note that Singh et
al. (1997) have demonstrated that the import of catalase
is very important for the metabolic functions of per-
oxisomes. They suggest that more-mildly affected pa-
tients, especially, may import sufficient levels of other
peroxisomal enzymes but have a more pronounced de-
fect in catalase import. The function of the imported
enzymes would be inhibited because of accumulation of
hydrogen peroxide in catalase-negative peroxisomes.
The probability that the G843D PEX1 protein is un-
stable is in line with the following data: PEX6 (MIM
601498), the second AAA protein involved in peroxi-
some biogenesis, has been identified as an interacting
partner for PEX1 by two-hybrid analysis and immu-
noprecipitation (Geisbrecht et al. 1998; Tamura et al.
1998b). In addition, the PEX phenotype of some PEX1-
deficient fibroblasts can be partially overcome by ex-
pression of PEX6 in certain cell lines (Geisbrecht et al.
1998). Interestingly, the susceptible cell lines are the ones
that carry the G843D mutation and thus have residual
PEX1 protein. No suppression was observed in cell lines
known to express no PEX1 protein. Similar results have
been reported for the yeast Pichia pastoris (Faber et al.
1998). It seems likely that overexpression of the inter-
acting protein PEX6 stabilizes some PEX1 protein, in a
way similar to the effects of temperature shifting. The
interaction between the G843D PEX1 protein (expressed
at 37C) and PEX6 is reduced by ∼70% compared with
the interaction with the wild-type PEX1 and PEX6 (Geis-
brecht et al. 1998). In addition, overexpression of the
G843D allele in PEX1-deficient cells at 37C suggested
a reduced function (15% of normal activity) as com-
pared with the wild-type allele (Reuber et al. 1997). If
we postulate that the reduction in PEX1 abundance re-
flects an error of PEX1 folding and that anything that
prevents this misfolding results in a greater amount of
correctly folded and active PEX1, then the effects de-
scribed above could be explained as follows: The ov-
erexpression of G843D PEX1 at 37C leads to the syn-
thesis of partially misfolded protein, which results in a
reduced capability of interaction with PEX6 and reduced
PEX1 function in general.
Misfolding as a Target for Pharmacological Treatment?
The difficulties encountered in an attempt to di-
vide—by phenotype—patients who have nonclassical ZS
and have the G843D allele into supgroups that have one
or two copies of the G843D allele may be explained by
the fact that the G843D PEX1 protein level depends on
other factors (not only on gene dosage) involved in the
folding and misfolding of the mutant protein. These fac-
tors include different levels of chaperones and differences
in the proteolytic degradation of the mutant protein,
both of which can be determined genetically or by en-
vironmental conditions. In addition, the temperature ef-
fect may be important and may represent a simple pa-
rameter to define further mutant alleles. The features of
the G843D protein present the intriguing possibility that
any actions that help to stabilize the residual protein
may be used for some kind of therapy for patients with
this kind of mutation. In this context, it is interesting to
note that a recent study of the pharmacological induc-
tion of peroxisomes in PBDs described the different re-
sponses, to treatment with 4-phenylbutyrate, of cells
from patients with ZS and cells from patients with
NALD or IRD (Wei et al. 2000). Although improvement
of peroxisomal function, measured by a two- to three-
fold increase in VLCFA oxidation and plasmalogen con-
centration, was observed in cells of patients with milder
phenotypes, this was not the case in cells of patients
with ZS. In addition, these authors showed that PEX1
and PEX6 mRNA was not increased in treated cells of
patients with milder CG1 phenotypes. Since we assume
that the improvement of peroxisomal function (VLCFA
oxidation and plasmalogen synthesis) in these patient
cells would require a gain in PEX1 function, 4-phenyl-
butyrate will be an interesting candidate for the inves-
tigation of pharmacological influence on PEX1 protein.
Almost 30% of all patients with PBD (excluding those
with RCDP) carry at least one G843D allele. An addi-
tional missense mutation (G593R) associated with low
PEX1 protein levels is a candidate for a similar phe-
notype. Imamura et al. (1998a, 1998b) have described
additional mutations, in other complementation groups,
with a cellular phenotype that is influenced by temper-
ature changes. This means that a large group of mildly
affected patients would probably benefit from therapeu-
tic efforts to stabilize the protein. Therefore, pharma-
cological agents should be screened via high-throughput
procedures. The observations of the present study pro-
vide a new target for causal pharmacological treatment
of patients with milder PBD phenotypes.
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